Market News / Story
argenx SE (ARGX) Reports Positive Phase 2 FB102 Data in Celiac Disease
·
argenx reported positive topline Phase 2 results for FB102 in adults with celiac disease, meeting the primary endpoint on Vh:Cd change vs placebo (p=0.0176) during gluten challenge, with supportive secondary measures and no new safety signals. The company plans to advance to Phase 3. Material Details #DetailAI Analyst View1Phase 2 primary endpoint metClinical validation de-risks the asset and supports progression to Phase 3, a key valuation driver.2Vh:Cd p=0.0176 vs…